SGAM
MACK

Smith Group Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Smith Group Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,278
Closed -$554K – 535
2015
Q3 		$554K Sell
8,278
-3
-0% -$245 0.02% 191
2015
Q2 		$806K Buy
8,281
+2,245
+37% +$214K 0.03% 181
2015
Q1 		$564K Buy
+6,036
New +$514K 0.02% 193
2013
Q4 		– Sell
-21,001
Closed -$626K – 453
2013
Q3 		$626K Buy
21,001
+2,590
+14% +$90.6K 0.03% 186
2013
Q2 		$976K Buy
+18,411
New +$807K 0.04% 182

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Smith Group Asset Management's MACK Position: Q4 2015 in Review

Smith Group Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 8,278 shares — an estimated $554K sold.

Smith Group Asset Management first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $976K in Q2 2013. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • Smith Group Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 8,278 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $554K.
  • Smith Group Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
  • Smith Group Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $976K in Q2 2013.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.